Relevance of the HPA‐15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes

Ertel, Katharina; Al-Tawil, Milad; Kroll, Hartmut

doi:10.1111/j.1537-2995.2005.04281.x

Cited by 70 publications

(77 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anti-HPA-3a, which is involved in at least 1-2% of cases, usually causes severe FNAIT [14]. In contrast, the clinical relevance of anti-HPA-15 alloabs for FNAIT is not yet clear [15]. The frequency of all other HPA alloabs is too low to estimate a clear relationship between specificity and clinical consequence.…”

Section: Alloimmune Thrombocytopenic Syndromesmentioning

confidence: 85%

Heterogeneity of Platelet Alloantigens and Alloantibodies: New Insights into Structure and Function

Socher

Kroll

2006

Transfus Med Hemother

Self Cite

View full text Add to dashboard Cite

Human platelet alloantigens (HPAs) and their corresponding alloantibodies (alloabs) play an essential role in fetal and neonatal alloimmune thrombocytopenia, posttransfusion purpura and platelet transfusion refractoriness. Emerging genotyping methods (e.g. microarray technology) will allow an automated throughput for HPA typing of large donor cohorts in the near future. For the clinical diagnosis of alloimmune thrombocytopenia, however, the proof of pathogenic alloabs still remains a prerequisite. Nowadays, monoclonal antibody-based antigen capture assays are the state of the art in many laboratories. This technique seems to come up against limiting factors. In a certain number of cases that are highly suspicious for alloimmune thrombocytopenia, platelet-specific alloabs are not detectable. Current observations indicate that these alloabs are heterogeneous in terms of their alloantigenic determinants as well as the consequences on platelet function. This heterogeneity may correlate to the severe bleeding complications sometimes seen in patients with alloimmune thrombocytopenia. New insights on the role of pathogenic alloabs will help us to improve diagnostic and therapeutic approaches for the adequate treatment of affected patients.

show abstract

Section: Alloimmune Thrombocytopenic Syndromesmentioning

confidence: 85%

Heterogeneity of Platelet Alloantigens and Alloantibodies: New Insights into Structure and Function

Socher

Kroll

2006

Transfus Med Hemother

Self Cite

View full text Add to dashboard Cite

show abstract

“…Three large series on human platelet antigen-specific alloantibodies implicated in cases of FNAITP have been published since 2000, which also provide data on HLA antibodies [9,14,15]. The first report shows that platelet-specific antibodies (including GPIV and CD36) were detected in 31% of 3,743 suspected cases referred for the evaluation of NAITP [9].…”

Section: New Series On Fnaitpmentioning

confidence: 99%

“…This became clear when HPA-15 became known as a possible target in FNAITP. In retrospective evaluations antibodies were detected in some of so far unsolved cases of suspected FNAITP [13][14][15]. Fetal platelets may absorb the maternal antibody and therefore the maternal serum may appear antibody negative.…”

Section: Serological Pitfallsmentioning

confidence: 99%

Controversy: HLA Antibodies Responsible for Fetal/Neonatal Alloimmune Thrombocytopenia – an Update

Panzer

2006

Transfus Med Hemother

View full text Add to dashboard Cite

This review focuses on reports and data dealing with an association between an alloimmunization against HLA class I antigens and fetal/neonatal alloimmune thrombocytopenia (FNAITP) that have been published since 2000. Current serological requirements for a presumed diagnosis of FNAITP in newborns are presented to understand the hesitation towards a diagnosis of HLA antibody- associated FNAITP. Three already published case reports are extensively discussed, and data from 3 series of presumed FNAITP are presented. Furthermore, the data on light chain restriction of such HLA antibodies are discussed in view of a possible clonality of these antibodies in presumed FNAITP.

show abstract

“…The use of fresh platelets is recommended to enhance the sensitivity of platelet antibody detection. [16][17][18] …”

mentioning

confidence: 99%

Platelet reactive alloantibodies responsible for immune thrombocytopenia in Malay population

Armawai¹,

Hassan²,

Wihadmadyatami

2014

Med J Indones

Self Cite

View full text Add to dashboard Cite

Abstrak HPA1a (n = 1),Methods: Sera from suspected FNAIT (n = 295) and PTR (n = 74) were collected in five years period (2008)(2009)(2010)(2011)(2012)(2013) and tested for the presence of platelet reactive antibodies by the use of antigen capture assay. Results:In 5/74 (5.41%) platelet specific antibodies against HPA-2b (n = 1), HPA-5a (n = 1), HPA-5b (n = 1), HPA-15b (n = 2) could be identified in our PTR cohort. In FNAIT cohort, platelet specific alloantibodies could be detected in 18 sera (6.10%) consisting anti-HPA-1a (n = 1), anti-HPA-3a (n = 3), anti-HPA-5a (n = 6), anti-HPA-5b (n = 6), anti-HPA-15a (n = 1), and anti-HPA-15b (n = 1). Conclusion:Our study indicates that anti-HPA-3, -HPA-5 and -HPA-15 antibodies seems to be the most platelet specific antibodies involved in FNAIT and PTR cases in Malaysian population. Since similar HPA allelic distribution among Malaysian and Indonesian populations have been observed, immunization against these three HPA systems are expected to be the most potential risk of alloimmune mediated platelet disorders in Indonesia.Keywords: alloimmune thrombocytopenia, transfusion pISSN: 0853-1773 • eISSN: 2252-8083 • http://dx.doi.org/10.13181/mji.v23i3.1011 • Med J Indones. 201423:158-62 Correspondence author: Sentot Santoso, sentot.santoso@immunologie.med.uni-giessen.deCl i n i c a l R e s e a r c h

show abstract

Relevance of the HPA‐15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes

Abstract: These observations indicate that alloimmunization against HPA-15 should be considered as a cause for immune thrombocytopenia, particularly in patients receiving multiple PLT transfusions.

Cited by 70 publications

References 31 publications

Heterogeneity of Platelet Alloantigens and Alloantibodies: New Insights into Structure and Function

Heterogeneity of Platelet Alloantigens and Alloantibodies: New Insights into Structure and Function

Controversy: HLA Antibodies Responsible for Fetal/Neonatal Alloimmune Thrombocytopenia – an Update

Platelet reactive alloantibodies responsible for immune thrombocytopenia in Malay population

Contact Info

Product

Resources

About